Safety, Tolerability and Host Response to Lactobacillus Johnsonii

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

42 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-08-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research study is to determine the effects of the probiotic, Lactobacillus johnsonii N6.2, on safety, gastrointestinal function, wellness, fecal bacteria and blood biomarkers in healthy individuals.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Role of Probiotics in Improving Quality of Life in Women With Functional Constipation

NCT03829358

Constipation - Functional

COMPLETED PHASE2/PHASE3

A Study to Investigate the Safety and Efficacy of a Probiotic on Gastrointestinal Health in Healthy Adults

NCT04223388

Gastrointestinal Health Healthy

UNKNOWN NA

Evaluation of Probiotics on Symptoms of Upper Respiratory Tract Infections

NCT00599430

Healthy

COMPLETED NA

Evaluation of Jarro-Dophilus EPS® Probiotic Formulations

NCT02693314

Healthy

COMPLETED NA

A Study of the Effects of Probiotics in Children Grades 1-3

NCT00635388

Healthy

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Healthy adult volunteers from 18-50 years of age will be recruited through the University of Florida and randomly distributed into two groups. This study is divided into 3 phases: baseline, intervention (study treatment) and washout. Participants will receive either the probiotic or placebo during the intervention phases. During the baseline phase, blood and fecal samples will be collected about 1 week before intervention initiation. On the day of a scheduled blood draw, the participant will need to arrive fasted overnight, and a light breakfast will be provided after blood draw. Starting on day 1 of the intervention phase, a second baseline blood sample will be collected and the participant will begin the study intervention (probiotic or placebo). Participants will consume 1 capsule (probiotic or placebo) daily for 8 weeks, and blood and stool samples will be collected and processed (on or around weeks 2, 4 and 8 of the intervention phase). A Fisher Scientific commode specimen collection system will be provided for stool collections. The stool collection kit may be taken home (participants will be asked to drop off the stool within 4 hours of defecation) for fecal sample collection or may use the restroom in the clinical lab at the Food Science and Human Nutrition Building in which kits will be provided for use. In the wash-out phase, participants will not consume the capsule (either the probiotic or placebo), but will provide blood and stool samples (on or around week 12). Throughout the study, participants will provide a total of 5 stool samples and 6 blood samples. Participants will be asked to complete daily and weekly questionnaires throughout all phases of the study, which will ask about quality of life (physical functioning, mental functioning, level of sleep, etc.), gastrointestinal function, and dietary intake. These assessments will be self-reported via online questionnaires. In the event that internet access is not available for a portion of the study, paper copies of the questionnaires may be provided.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Probiotic

L. johnsonii N6.2 10\^10 CFU in capsule form administered for 8 weeks

Group Type ACTIVE_COMPARATOR

L. johnsonii N6.2

Intervention Type BIOLOGICAL

L. johnsonii N6.2 10\^10 CFU in capsule form administered for 8 weeks

Placebo

Encapsulated starch placebo administered for 8 weeks

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type BIOLOGICAL

Encapsulated starch placebo administered for 8 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

L. johnsonii N6.2

L. johnsonii N6.2 10\^10 CFU in capsule form administered for 8 weeks

Intervention Type BIOLOGICAL

Placebo

Encapsulated starch placebo administered for 8 weeks

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Lactobacillus

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* To participate in the study individuals must

* be 18-50 years old.
* be willing to complete multiple questionnaires via computer.
* be willing to take the probiotic or placebo capsule daily for 8 weeks.
* be willing to provide 1 stool during weeks 0, 2, 4, 8 and 12 of the study.
* be willing to provide blood samples at weeks -1, 0, 2, 4, 8 and 12 of the study.
* have daily access to a computer with internet access for the entire 13-wk study.
* be willing to provide a social security number

Exclusion Criteria

* To participate in the study individuals must NOT

* currently take medications for constipation, diarrhea or psychological disorders (depression, anxiety, insomnia etc.).
* have taken antibiotics within the past four weeks prior to randomization.
* currently take probiotic supplements and do not want to discontinue a minimum of two weeks prior to the study
* have had or are currently being treated for any diseases or illnesses such as gastrointestinal disease (gastric ulcers, Crohn's, ulcerative colitis, etc.), chronic disease like diabetes or kidney disease, immune-compromising diseases or conditions (HIV, AIDS, hepatitis, cancer, transplant patient etc.)
* currently receive medical treatment for stress induced symptoms/disorders
* be a current smoker

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes